Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

PET/CT in therapy evaluation of patients with lung cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Immunosuppression and risk of cervical cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

FDG-PET/CT is a well documented and widespread used imaging modality for the diagnosis and staging of patient with lung cancer. FDG-PET/CT is increasingly used for the assessment of treatment effects during and after chemotherapy. However, PET is not an accepted surrogate end-point for assessment of response rate in clinical trials. The aim of this review is to present current evidence on the use of PET in response evaluation of patients with lung cancer and to introduce the pearls and pitfalls of the PET-technology relating to response assessment. Based on this and relating to validation criteria, including stable technology, standardization, reproducibility and broad availability, the review discusses why, despite numerous studies on response assessment indicating a possible role for FDG-PET/CT, PET still has no place in guidelines relating to response evaluation in lung cancer.

OriginalsprogEngelsk
TidsskriftExpert Review of Anticancer Therapy
Vol/bind14
Udgave nummer5
Sider (fra-til)595-620
Antal sider26
ISSN1473-7140
DOI
StatusUdgivet - maj 2014

ID: 45026268